GALECTO INC (GLTO) Stock Price, Forecast & Analysis
NASDAQ:GLTO • US36322Q2066
GLTO Key Statistics, Chart & Performance
The current stock price of GLTO is 30 USD. In the past month the price increased by 1.42%. In the past year, price increased by 565.19%.
GLTO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GLTO. When comparing the yearly performance of all stocks, GLTO is one of the better performing stocks in the market, outperforming 99.54% of all stocks.
GLTO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLTO. The financial health of GLTO is average, but there are quite some concerns on its profitability.
GLTO Financial Highlights
Over the last trailing twelve months GLTO reported a non-GAAP Earnings per Share(EPS) of -17.62. The EPS increased by 51.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -147.58% | ||
| ROE | -197.88% | ||
| Debt/Equity | 0 |
GLTO Forecast & Estimates
8 analysts have analysed GLTO and the average price target is 41.48 USD. This implies a price increase of 38.27% is expected in the next year compared to the current price of 30.
GLTO Ownership
GLTO Latest News, Press Relases and Analysis
GLTO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GLTO
Company Profile
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2020-10-29. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. The company is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Company Info
GALECTO INC
75 State Street, Suite 100
Boston MASSACHUSETTS DK-2200 US
CEO: Hans T. Schambye
Employees: 5
Phone: 14570705210
GALECTO INC / GLTO FAQ
What does GLTO do?
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2020-10-29. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. The company is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Can you provide the latest stock price for GALECTO INC?
The current stock price of GLTO is 30 USD. The price decreased by -1.51% in the last trading session.
Does GLTO stock pay dividends?
GLTO does not pay a dividend.
What is the ChartMill technical and fundamental rating of GLTO stock?
GLTO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does GALECTO INC belong to?
GALECTO INC (GLTO) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of GLTO stock?
GALECTO INC (GLTO) has a market capitalization of 48.00M USD. This makes GLTO a Nano Cap stock.
Can you provide the upcoming earnings date for GALECTO INC?
GALECTO INC (GLTO) will report earnings on 2026-03-17, after the market close.